Hyderabad, May 16 -- Dr. Reddy's Laboratories, the Hyderabad-based global pharmaceutical major, on Saturday announced the launch of its generic Semaglutide Injection in Canada.
Dr. Reddy's is among the first companies to introduce a generic Semaglutide Injection in the Canadian market following the Notice of Compliance (NOC) granted by Health Canada on April 28, 2026.
Canada has become the first G7 nation to grant market authorisation for generic Semaglutide Injection, marking a significant milestone in the global expansion of GLP-1 therapies, the pharmaceutical company said in a release here.
According to the company, the launch reflects Dr. Reddy's preparedness to ensure rapid patient access following regulatory approval.
In Canada, D...